Please sign in to follow a disease.
Simple urine test could spot prostate cancer early
NCT ID NCT06347809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether DNA markers found in urine can help detect prostate cancer. Researchers collected urine and prostate fluid samples from 24 men with or suspected of having prostate cancer. The goal was to see how accurate these markers are and to understand patient opinions on this type of screening.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, non-invasive urine test to help detect prostate cancer earlier.
- What could go wrong
- This is an early, terminated study with only 24 participants, so results may not be reliable or widely applicable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
24 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with diagnosis of prostate carcinoma/adenocarcinoma with a corresponding Gleason score OR is scheduled for a prostate biopsy for an elevated PSA, palpable prostate nodule, an abnormal imaging finding, or worrisome PSA velocity.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \* Patient is 18 years or older * Patient has a histologically confirmed diagnosis of prostatic carcinoma/adenocarcinoma with a corresponding Gleason score OR is scheduled for a prostate biopsy for an elevated Prostate Specific Antigen (PSA), palpable prostate nodule, an abnormal imaging finding, or worrisome PSA velocity Exclusion Criteria: * \* Patient has had a transplant prior to sample collection * Patient has had Androgen (e.g. Flutamide, Androcur, Casodex, Nilandron) or Luteinizing hormone-releasing hormone (LHRH) (e.g. Lupron, Zoladex) therapy * Patient has transurethral instrumentation (cystoscopy, placement of urinary catheter) within the 7 days prior to sample collection * Patient has chronic indwelling urinary catheter * Patient has had a urinary tract infection within the 14 days prior to sample collection * Patient has immunotherapy (e.g. Kwon study drugs) for prostate cancer prior to sample collection * Patient has a history of bladder cancer * Patient has had a biopsy within the last 6 weeks (excluding non-melanoma skin biopsies) of sample collection * Patient has had surgery to completely remove current target pathology prior to sample collection * Patient has a prior history of prostate carcinoma/adenocarcinoma * Patient has received chemotherapy class drugs (e.g. Docetaxel, Methotrexate) within the 5 years prior to sample collection * Patient has received therapeutic radiation prior to sample collection * Patient has had focal ablation \[e.g. High-intensity focused ultrasound (HIFU) or cryoablation\] of prostate cancer prior to sample collection * Patient has known primary cancer outside of the prostate within the last 5 years (not including basal cell or squamous cell skin cancers) of sample collection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Can a One-Two radiation punch improve prostate cancer control?
- Can a special PET scan change the course of prostate cancer?
- Can a High-Tech radiation beam hit prostate tumors without harming healthy tissue?
- Can 3D imaging make prostate radiation more precise and worth the cost?